Cas no 117704-25-3 (Doramectin)

Doramectin is a macrocyclic lactone belonging to the avermectin class, widely used as a broad-spectrum antiparasitic agent in veterinary medicine. It exhibits potent activity against both endoparasites (e.g., gastrointestinal nematodes, lungworms) and ectoparasites (e.g., mites, lice). Doramectin’s lipophilic nature ensures prolonged systemic exposure, enabling sustained efficacy with a single dose. It operates by binding to glutamate-gated chloride channels in parasites, causing paralysis and death. The compound is noted for its high bioavailability and safety profile in livestock, including cattle, sheep, and swine. Its extended persistence in tissues reduces the frequency of administration, making it a practical choice for parasite control programs. Resistance management remains a consideration in long-term use.
Doramectin structure
Doramectin structure
Product Name:Doramectin
CAS No:117704-25-3
MF:C50H74O14
MW:899.1142
MDL:MFCD00894747
CID:63309
PubChem ID:139585898
Update Time:2026-04-16

Doramectin Chemical and Physical Properties

Names and Identifiers

    • Doramectin
    • 25-CYCLOHEXYL-5-O-DEMETHYL-25-DE(1-METHYLPROPYL)AVERMECTIN
    • Doramectin VETRANAL
    • Doromectin
    • bridged fused ring systems nomenclature: (2aE,4E,8E)-(5’S,6S,6’R,7S,11R,13S,15S,17aR,20R,20aR,20bS)-6’-cyclohexyl-5’,6,6’,7,10,11,14,15,17a,20,20a,20b-dodecahydro-20,20b-dihydroxy-5’,6,8,19-tetramethyl-17-oxospiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2’-[2H]pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabino-hexopyranoside
    • DONGGUAI
    • Spiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2'-[2H]pyran],avermectin A1a deriv.
    • 25-Cyclohexylavermectin B1
    • Dectomax
    • L701023
    • UK 67994
    • KGD7A54H5P
    • Doramectinum [INN-Latin]
    • Doramectine [INN-French]
    • Doramectina [INN-Spanish]
    • Doramectin [USAN:INN:BAN]
    • Doramectine
    • Doramectinum
    • Doramectina
    • C50H74O14
    • UK 67,994
    • Cyclohexylavermectin B1
    • DSSTox_RID_83176
    • DSSTox_CID_28908
    • DSSTox_GSID_48982
    • Avermectin A(sub 1a), 25-cycloh
    • Q906534
    • SCHEMBL3464636
    • MDL： MFCD00894747
    • Inchi： 1S/C50H74O14/c1-27-13-12-16-34-26-57-47-42(51)30(4)21-37(50(34,47)54)48(53)60-36-22-35(63-49(25-36)20-19-29(3)45(64-49)33-14-10-9-11-15-33)18-17-28(2)44(27)61-41-24-39(56-8)46(32(6)59-41)62-40-23-38(55-7)43(52)31(5)58-40/h12-13,16-17,19-21,27,29,31-33,35-47,51-52,54H,9-11,14-15,18,22-26H2,1-8H3/b13-12+,28-17+,34-16+/t27-,29-,31-,32-,35+,36-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47+,49+,50+/m0/s1
    • InChI Key： QLFZZSKTJWDQOS-YDBLARSUSA-N
    • SMILES： O1[C@]2(C([H])=C([H])[C@]([H])(C([H])([H])[H])[C@@]1([H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C([H])([H])[C@]1([H])C([H])([H])[C@@]([H])(C([H])([H])C([H])=C(C([H])([H])[H])[C@]([H])([C@@]([H])(C([H])([H])[H])C([H])=C([H])C([H])=C3C([H])([H])O[C@]4([H])[C@@]([H])(C(C([H])([H])[H])=C([H])[C@@]([H])(C(=O)O1)[C@@]43O[H])O[H])O[C@@]1([H])C([H])([H])[C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[C@@]1([H])C([H])([H])[C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])OC([H])([H])[H])OC([H])([H])[H])O2 |c:47,62,66|

Computed Properties

  • Exact Mass: 898.50800
  • Monoisotopic Mass: 898.508
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 3
  • Hydrogen Bond Acceptor Count: 14
  • Heavy Atom Count: 64
  • Rotatable Bond Count: 7
  • Complexity: 1790
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 17
  • Undefined Atom Stereocenter Count : 2
  • Defined Bond Stereocenter Count: 3
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 170
  • XLogP3: 4.5

Experimental Properties

  • Color/Form: White to off white crystalline powder
  • Density: 1.25
  • Melting Point: 162-168°C
  • Boiling Point: 967.4°C at 760 mmHg
  • Flash Point: 967.4 °C at 760 mmHg
  • Refractive Index: 1.579
  • Solubility: methanol: soluble
  • PSA: 170.06000
  • LogP: 5.91160

Doramectin Security Information

Doramectin Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
D127678-1g
Doramectin
 117704-25-3 98%
1g
 ￥425.90 2023-09-03
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
D127678-5g
Doramectin
 117704-25-3 98%
5g
 ￥1337.90 2023-09-03
S e l l e c k ZHONG GUO
S5117-25mg
Doramectin
 117704-25-3 99.86%
25mg
 ￥794.7 2023-09-15
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R018880-1g
Doramectin
 117704-25-3 98%
1g
 ￥391 2024-05-26
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R018880-5g
Doramectin
 117704-25-3 98%
5g
 ￥1229 2024-05-26
ChemScence
CS-0736-10mg
Doramectin
 117704-25-3 98.96%
10mg
 $50.0 2022-04-28
ChemScence
CS-0736-50mg
Doramectin
 117704-25-3 98.96%
50mg
 $70.0 2022-04-28
ChemScence
CS-0736-100mg
Doramectin
 117704-25-3 98.96%
100mg
 $95.0 2022-04-28
TRC
D534500-10mg
Doramectin
 117704-25-3
10mg
 $ 170.00 2023-09-07
TRC
D534500-100mg
Doramectin
 117704-25-3
100mg
 $ 724.00 2023-09-07

Doramectin Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:117704-25-3)Doramectin
Order Number:sfd9159
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:35
Price ($):discuss personally
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:117704-25-3)Doramectin
Order Number:LE12184;LE27065660
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:06
Price ($):discuss personally

Doramectin Spectrogram

13C NMR
13C NMR
1H NMR 300 MHz DMSO
1H NMR

Doramectin Related Literature

Related Categories

Additional information on Doramectin

Doramectin and Its Applications in Modern Veterinary Medicine

Doramectin, a compound with the CAS number 117704-25-3, has emerged as a cornerstone in the realm of veterinary medicine due to its potent anthelmintic properties. This macrocyclic lactone derivative belongs to the family of avermectins, a class of compounds renowned for their efficacy against a wide range of parasitic infections in animals. The unique chemical structure of Doramectin, characterized by its 16-membered lactone ring and specific amino acid substitutions, contributes to its high selectivity and low toxicity profile, making it an indispensable tool in the fight against parasitic diseases.

The development and application of Doramectin have been extensively studied and refined over the past few decades. Its mechanism of action involves the activation of glutamate-gated chloride channels in parasitic nematodes, leading to paralysis and subsequent death of the parasites. This targeted approach has not only improved the effectiveness of treatments but also minimized side effects on the host animals. The compound's broad spectrum activity makes it effective against various internal and external parasites, including those that cause significant economic losses in livestock industries worldwide.

Recent advancements in pharmacokinetic studies have further highlighted the versatility of Doramectin. Research indicates that the compound exhibits prolonged half-life in animal systems, allowing for less frequent dosing regimens. This attribute is particularly beneficial in field conditions where consistent treatment schedules may be challenging to maintain. Additionally, studies have demonstrated that Doramectin's stability under various environmental conditions enhances its practicality for use in diverse geographical locations.

The impact of Doramectin on livestock health and productivity cannot be overstated. By effectively controlling parasitic infections, Doramectin helps to improve animal welfare, enhance growth rates, and increase milk production. These benefits translate into significant economic gains for farmers and veterinarians alike. Moreover, the compound's role in reducing zoonotic disease transmission by controlling vector-borne parasites underscores its importance in public health initiatives.

In recent years, there has been growing interest in exploring the potential applications of Doramectin beyond traditional veterinary use. Preliminary research suggests that certain derivatives of this compound may have applications in human medicine, particularly in the treatment of parasitic infections that are resistant to conventional therapies. While further studies are needed to validate these findings, they open up exciting possibilities for future research and development.

The synthesis and formulation of Doramectin have also seen significant innovations. Modern synthetic methodologies have enabled the production of higher purity grades of the compound, reducing impurities that could potentially affect its efficacy or safety profile. Furthermore, advancements in formulation technologies have led to the development of novel delivery systems, such as injectable solutions and pour-on formulations, which improve ease of administration and user convenience.

Environmental considerations have also played a crucial role in the development and use of Doramectin. Efforts have been made to minimize environmental impact through responsible drug disposal practices and the development of formulations with reduced environmental persistence. These measures are essential in ensuring that the benefits of Doramectin are realized without compromising ecological balance.

The regulatory landscape surrounding Doramectin reflects its importance in veterinary medicine. Regulatory agencies worldwide have stringent guidelines to ensure its safe and effective use. These guidelines cover aspects such as dosage recommendations, withdrawal periods before meat or milk enters the food chain, and monitoring for any potential residues. Compliance with these regulations is crucial for maintaining public trust and ensuring animal health standards.

Future research directions for Doramectin include exploring new applications in companion animal medicine and investigating potential synergistic effects when combined with other anthelmintic agents. The ongoing development of resistance by parasitic populations necessitates continuous innovation to maintain the efficacy of Doramectin over time. Collaborative efforts between researchers, veterinarians, and industry stakeholders are essential to address this challenge effectively.

In conclusion, Doramectin stands as a testament to the progress made in veterinary medicine through targeted pharmacological interventions. Its unique properties, broad spectrum activity, and favorable safety profile make it an invaluable asset in controlling parasitic infections. As research continues to uncover new possibilities for its use and refinement, Doramectin is poised to remain at the forefront of veterinary care for years to come.

117704-25-3 (Doramectin) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:117704-25-3)Doramectin
sfd9159
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:117704-25-3)Doramectin
LE12184;LE27065660
Purity:99%/99%
Quantity:25KG,200KG,1000KG/25KG,200KG,1000KG
Price ($):Inquiry/Inquiry
Email